Susquehanna Fundamental Investments’s Spero Therapeutics SPRO Stock Holding History

Susquehanna Fundamental Investments’s Portfolio SPRO Stock Details SPRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$35.6K	Buy	+16,095	New	+$42.1K	﹤0.01%	733

Other funds holding SPRO

GSK plc London $602M AUM

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Susquehanna Fundamental Investments's SPRO Position: Q2 2026 in Review

Susquehanna Fundamental Investments opened a new position in Spero Therapeutics (SPRO) in Q2 2026: 16,095 shares worth $35.6K. The stake represents ﹤0.01% of the portfolio and ranks #733 among its holdings.

60 funds tracked by Wall St. Rank hold SPRO as of Q2 2026.

Susquehanna Fundamental Investments held 16,095 shares of Spero Therapeutics worth $35.6K as of Q2 2026.
Spero Therapeutics was a new Susquehanna Fundamental Investments position in Q2 2026.
Spero Therapeutics made up ﹤0.01% of Susquehanna Fundamental Investments's portfolio in Q2 2026, its #733 holding.
60 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2026.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2026, filed 14 Aug 2026.